Sleep-related breathing disorders in young adults with Prader-Willi syndrome: a placebo-controlled, cross-over GH trial.
Sleep-related breathing disorders (SRBD) are common in people with Prader-Willi syndrome (PWS). Young adults with PWS benefit from GH continuation after adult height by maintaining the improved body composition obtained during childhood. There are, however, no studies about the effects of GH on SRBD in young adults with PWS who were treated with GH during childhood. To investigate the effects of GH versus placebo on SRBD in young adults with PWS who were treated with GH during childhood and had attained adult height. 2-year, randomized, double-blind, placebo-controlled, cross-over GH-study in 27 young adults with PWS, stratified for gender and BMI. Dutch PWS Reference Center. Cross-over intervention with GH (0.67 mg/m2/day) and placebo, both during one year. Apnea hypopnea index (AHI), obstructive apnea index (OAI), central apnea index (CAI), measured by polysomnography. Compared to placebo, GH treatment did not increase AHI, CAI or OAI (p>0.35). The effect of GH versus placebo was neither different between men and women, nor between patients with a deletion or mUPD/ICD. After 2 years, there was no difference in AHI, CAI or OAI compared to baseline (p>0.18). Two patients (7%) fulfilled the criteria of obstructive sleep apnea (OSA), regardless of GH or placebo. GH compared to placebo does not cause a significant increase in AHI, CAI or OAI in adults with PWS who were treated with GH during childhood and have attained adult height. Our findings are reassuring and prove that GH can be safely administered.